ABSTRACT
Objective: Vaccines are one of the promising approaches to control the pandemic. The aim of this study, which was conducted on healthcare workers who previously were or were not infected with COVID-19, was to evaluate the undesirable effects that developed after the CoronaVac (Sinovac Life Sciences, Beijing, China). Methods: Volunteers who were administered the first dose of inactivated CoronaVac vaccine between January 14-24, 2021, were included in this retrospective study. Demographic information was obtained from the questionnaire results and from the data of the applications made due to side effects. Results: 911 healthcare workers, 232 of whom had a history of COVID-19 were included in the study. The mean age of those with a history of COVID-19, was 36 (20-66), and 33.6% were men. 26.7% were doctors, 34.9% were nurses, 155 (66.8%) worked in internal and 62 (26.7%) in surgical units. There was no significant difference between the two groups regarding age, gender, task, and the departments they worked in. Comorbidities were present in 25.9% of the group with a history of COVID-19;the most common disease was asthma (5.6%). Allergy history was 4.3% in the group with COVID-19 and 7.8% in the other group (p=0.070). The incidence of post-vaccine adverse events (62.9%) was higher in those with a history of COVID-19 than in those without (57.1%). The most common adverse event was a headache, and it was significantly higher in the group who had COVID-19 compared to those who had not (36.6% vs. 27.7%;p=0.01). Conclusion: In our study, we observed that the rates of undesirable effects after vaccination were high in individuals with a history of COVID-19. Although it is thought that this situation may be related to the developing antibody response rates, the insufficient number of cases and the lack of determination of the antibody response after infection and vaccination are a disadvantage of the study.
ABSTRACT
Objective: Vaccines are one of the promising approaches to control the pandemic. The aim of this study, which was conducted on healthcare workers who previously were or were not infected with COVID-19, was to evaluate the undesirable effects that developed after the CoronaVac (Sinovac Life Sciences, Beijing, China). Method(s): Volunteers who were administered the first dose of inactivated CoronaVac vaccine between January 14-24, 2021, were included in this retrospective study. Demographic information was obtained from the questionnaire results and from the data of the applications made due to side effects. Result(s): 911 healthcare workers, 232 of whom had a history of COVID-19 were included in the study. The mean age of those with a history of COVID-19, was 36 (20-66), and 33.6% were men. 26.7% were doctors, 34.9% were nurses, 155 (66.8%) worked in internal and 62 (26.7%) in surgical units. There was no significant difference between the two groups regarding age, gender, task, and the departments they worked in. Comorbidities were present in 25.9% of the group with a history of COVID-19;the most common disease was asthma (5.6%). Allergy history was 4.3% in the group with COVID-19 and 7.8% in the other group (p=0.070). The incidence of post-vaccine adverse events (62.9%) was higher in those with a history of COVID-19 than in those without (57.1%). The most common adverse event was a headache, and it was significantly higher in the group who had COVID-19 compared to those who had not (36.6% vs. 27.7%;p=0.01). Conclusion(s): In our study, we observed that the rates of undesirable effects after vaccination were high in individuals with a history of COVID-19. Although it is thought that this situation may be related to the developing antibody response rates, the insufficient number of cases and the lack of determination of the antibody response after infection and vaccination are a disadvantage of the study.Copyright © 2023, DOC Design and Informatics Co. Ltd. All rights reserved.
ABSTRACT
Today, it is widely used on DDI. is an important problem. machine with Natural Language Processing understand human language and facilitate human life is targeted. Word preprocessing, information extraction, machine translation, text summarization and classification studies DDI are some of the application areas. Education, business and social Studies on DDI in almost every sector such as media available. Declaring a pandemic due to the Covid19 Virus in the world DDI became important in the health sector after the won. Studies on Turkish texts scarcity and the need for DDI applications in the field of health makes the work important. Turkish Radiology A dataset was created from the reports. Data NLTK, A set of rules specified by the mainspring and regular expressions. preprocessed and normalized. later Language modeling was carried out with Word2Vec. © 2022 IEEE.
ABSTRACT
BACKGROUND/AIM: Asymptomatic infections are not low in their inability to spread the virus and have no special clinical signs. Consequently, the detection of asymptomatic infections is the central issue for early prevention and control of the coronavirus disease-2019 (COVID-19) around the world. This study aimed to assess the demographic, clinical, and laboratory findings of symptomatic and asymptomatic patients with a diagnosis of COVID-19. MATERIALS AND METHODS: In this retrospective single-center study, 165 laboratory-confirmed COVID-19 patients who were asymptomatic or symptomatic and followed up at home or in the hospital between March 15, 2020, and May 23, 2020, were included. RESULTS: Among all 165 patients, 21 (12.7%) were asymptomatic and 144 (87.2%) were symptomatic. The median age of the symptomatic patients was higher than the asymptomatic patients, and there were no asymptomatic patients over 65 years older. Twenty-one patients were asymptomatic at admission, but four of them (19%) developed symptoms in the follow-up. Although the white blood cell (WBC) and lymphocyte counts were within the normal range for all patients, the asymptomatic patients had a significantly higher WBC and lymphocyte count than the symptomatic patients. The symptomatic patients had higher median C-reactive protein levels than the asymptomatic patients. For the typical CT findings for COVID-19, there were fewer in the asymptomatic infections (12 cases, 57.1%) than those in the symptomatic infections (103 cases, 71.5%). There were 17 (10%) patients in need of intensive care and the mortality rate was 6.1%. CONCLUSION: Asymptomatic infections spread silently in COVID-19. More importance should be given to the identification and quarantine of asymptomatic patients to eliminate COVID-19 transmission and to allow for the early diagnosis of pre-symptomatic patients.
ABSTRACT
Objective: The aim of this study was to investigate the impact of sex-specific genetic factors in the pathogenesis and prog-nosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2)-induced macrophage activation syndrome (MAS), independent of age and comorbidity presence. Material(s) and Method(s): Patients aged 18-50 years who had been diagnosed with coronavirus 2019 (COVID-19), the disease caused by the SARS-CoV2 virus, were enrolled in a prospective, case-control, multi-center study. Genetic alterations and messenger RNA (m-RNA) expression levels of the TLR7, TLR8, ACE2, CD40L, CXCR3, and TASL genes were determined using DNA sequencing analysis, and gene expression was determined using quantitative reverse transcriptase polymerase chain reaction testing. PolyPhen-2 (Polymorphism Phenotyping v2;Adzhubei et al., 2010) and SNAP2 (Rostlab, Munich, Germany) genetic analysis tools were used to define the pathogenic effects of detected mutations by sequencing the selected genes in hotspot regions. Result(s): The study group consisted of 80 patients diagnosed with COVID-19 and was divided into groups based on sex and MAS status. Twenty-nine mutations were detected in 6 genes. Among the alterations, 15 were identified in this study for the first time and 9 were pathogenic. Pathogenic missense mutations in the TLR7, TLR8, ACE2, and TASL genes were detected in the MAS (+) group. In males, decreased TLR7, TLR8, and CXCR3 expression was statistically significant in the MAS (+) group (p<0.050). CXCR3 expression was lower in the female and male MAS (+) groups compared with the MAS (-) groups (p<0.050). Conclusion(s): In the absence of major risk factors for COVID-19, the TLR7/8, ACE2, and CXCR3 variants and decreased m-RNA expression levels associated with genetic susceptibility may be independent prognostic risk factors for COVID-19. Copyright © 2022 by Erciyes University Faculty of Medicine.
ABSTRACT
Aim: To meet the increasing intensive care and mechanical ventilator needs during the COVID-19 pandemic process, parameters that will enable rapid assessment and decision-making at the bedside are required in emergency services. The aim is to provide rational use of intensive care units by determining appropriate parameters that can be used to evaluate the intensive care follow-up indication. Material and Methods: Demographic data,vital signs, and hemogram results were recorded during the consultation in terms of intensive care follow-up requirements of the patients. The qSOFA, shock index, modified shock index, and the neutrophil-lymphocyte ratio were calculated. Results: Three hundred patients were included in the study.The median age was 69.2 years, 88% of the patients had at least one comorbid disease. The neutrophil-lymphocyte ratio was significant in predicting the need for intubation, but is not an independent risk factor. Male gender, qSOFA scores and need for intubation were predictors of intensive care mortality. Discussion: We found out that no scoring system can predict the requirement of intubation, but qSOFA is effective in showing mortality when making intensive care follow-up decisions for COVID-19 patients consulted in emergency departments.
ABSTRACT
Aim: It is known that the Coronavirus disease-2019 (COVID-19) does not only affect the respiratory system in the body, but also affects many vital systems. In this study, we aimed to investigate polymerase chain reaction (PCR) positivity rates in urine samples of patients with COVID-19 infection and to evaluate the effectiveness of positron emission tomography/computed tomography (PET/CT) in demonstrating renal involvement in patients with urinary system involvement findings. Methods: Patients who had positive COVID-19 PCR test and were hospitalized in Erciyes University pandemic wards due to COVID-19 infection between June 2020 and December 2020 were included in this prospective study. A urine PCR test was applied to all patients. In addition, PET/CT was performed in patients with no known malignancy, clean urine culture, but suspected COVID-19 urinary system involvement. Results: A total of 66 patients with a mean age of 45.4±9.1 years were included in the study. PET/CT was performed at the same time in 6 of these patients with suspected urinary system involvement. Only 1 (1.5%) of 66 patients had a positive urine PCR test. No abnormal genitourinary PET/CT findings were found in any of the patients. Conclusion: Urine PCR positivity is very rare in patients with COVID-19 infection. In addition, according to our results, it can be said that PET/CT is not an effective imaging method to show COVID-19 urinary system involvement.
ABSTRACT
Introduction: Oral cladribine is a licensed disease-modifying treatment (DMT) for highly active relapsing multiple sclerosis (RMS). We report clinical and paraclinical data collected as part of ongoing follow-up of our cohort of people with MS (pwMS) treated with subcutaneous (s.c.) cladribine personalised dosing (CPD). Objectives and Aims: To report follow-up data in pwMS treated using CPD (adjusted for weight and total lymphocyte count, TLC). Methods: CPD was offered to pwMS with signs of disease activity irrespective of their disease course. Cladribine 10 mg s.c. was given on three consecutive days (four in pwMS & gt;90kg) during week 1. Based on TLC at week 4, patients were given another 0-3 doses at week 5. A second cycle of CPD was administered 11 months later. Follow-up included recording of adverse events, relapses, annual EDSS, 9-hole peg, timed 25-foot walking, and symbol digit modalities tests. MRI (gadolinium enhancing T1 and T2 lesions), cerebrospinal fluid (CSF) neurofilament light chain (NfL) measurements and full blood counts were obtained. Results: 250 pwMS (113 RMS, 137 PMS) received CPD. 211/250 completed a second cycle. Baseline age 45 (17-72) years and baseline EDSS 0-8.5. The safety and tolerability profile of CPD was generally very good. Six severely disabled pwMS died (one each from influenza, encephalitis, hypoxic brain injury due to choking, COVID19 pneumonia, haemopericardium and dissecting aortic aneurysm and unknown [prior EDSS 9.5]). One myocardial infarction, two breast cancers, one pulmonary embolism occurred, and three severe allergic skin reactions without long term sequelae. Severe lymphopenia (WHO grade 3-4) occurred in 7% despite personalised dosing. In 74/155 pwMS (47.7% of those with EDSS data available), EDSS remained stable or improved at follow up (median 2.9 years). In n=37, mean pre- and post-treatment CSF-NfL measurements at -4.4 and 11.3 months, respectively, were 1079pg/ml (CI 557, 1601) and 508pg/ml (CI 330, 686). Conclusions: Our ongoing observations of this uncontrolled real world cohort suggests CPD is a safe, well tolerated treatment for pwMS with disease activity. Efficacy of cladribine in preserving upper limb function in advanced MS (EDSS 6.5-8.5) will be tested in the ChariotMS trial.
ABSTRACT
Objective: Since the New Coronavirus Disease (COVID-19) can also be spread by asymptomatic individuals, identifying asymptomatic carriers is critical in the fight against the COVID-19 pandemic. We aimed to describe the COVID-19 poly-merase chain reaction (PCR) test positivity rate sent before the operation / interventional procedure in asymptomatic individuals and determine an estimated time for the pandemic’s decay time. Methods: All the patients over the age of 18 who were obtained the COVID-19 PCR test before the operation or interven-tional procedure between July 1 and October 31, 2020 were included. The patients were divided into two groups according to the periods when the peak was experienced or not. Results: 1070 patients were included in the study. PCR positivity was detected in 55 (5.14%) of the patients. The mean case incidence rate was 0.76% (2/263) in the months when the study was conducted, and there was no COVID-19 peak, and 6.57% (53/807) in the months when the peak was observed. These rates were taken as a reference for the months with and without a peak. The time to reach 67%, which is accepted as the herd immunity limit, was calculated by adding 6.57% to the months corresponding to peak periods with 20-day periods starting from April 1, and the rate of 0.76% to the other months. Since there were two peaks after April 2020, the mass immunity rate reached until today has been calculated. If the COVID-19 peak would not happen since this date, the possible pandemic attenuation time was predicted as March 2022, and if only one peak would happen, then predicted as May 2021. Conclusion: The incidence fluctuates with the restrictions, the risk of re-infection, the virus being open to new mutations, and the initiation of vaccination programs make it difficult to predict the pandemic attenuation time.
ABSTRACT
Objective: Since the first case from Wuhan, China in December 2019, COVID-19 has spread all over the world and a pandemic was declared by the World Health Organization on January 30, 2020. While there are no specific effective antiviral drugs or vaccines to treat or to prevent COVID-19;favipiravir, hydroxychloroquine and their combination are used in the treatment of COVID-19 in Turkey. In this study, it was aimed to evaluate the demographic, clinical and laboratory findings, the treatments given and the effects of treatments on liver tests of the patients followed up with the diagnosis of COVID-19.